Clinical trials for Metaplastic carcinoma

The European Union Clinical Trials Register allows you to search for protocol and results information on:

interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC

clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
Clinical Trials Information System (CTIS).

The EU Clinical Trials Register currently displays 44338 clinical trials with a EudraCT protocol, of which 7368 are clinical trials conducted with subjects less than 18 years old. The register also displays information on 18700 older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).

Examples: Cancer AND drug name. Pneumonia AND sponsor name.
How to search [pdf]

Advanced Search:

Search tools

Select Country:	Select Age Range:
Select Trial Status:	Select Trial Phase:
Select Gender:
Select Date Range: to
Select Rare Disease:
IMP with orphan designation in the indication
Orphan Designation Number:
Results Status:
Clear advanced search filters

Trials with a EudraCT protocol (13)
Paediatric studies in scope of Art45 of the Paediatric Regulation (0)

13 result(s) found for: Metaplastic carcinoma. Displaying page 1 of 1.

EudraCT Number: 2007-005090-65

Sponsor Protocol Number: VALPAX

Start Date*: 2007-10-18

Sponsor Name:AZIENDA SANITARIA OSPEDALIERA "S. GIOVANNI BATTISTA DI TORINO"

Full Title: New therapeutic approaches in the treatment of anaplastic thyroid cancer: a phase II trial of valproic acid and paclitaxel in solid tumours

Medical condition: Patients with anaplastic thyroid cancer or with metastatic solid tumours

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	9.1		10002240	Anaplastic thyroid cancer	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: IT (Ongoing)

Trial results: (No results available)

EudraCT Number: 2008-005221-11

Sponsor Protocol Number: MUTAVA

Start Date*: 2008-10-22

Sponsor Name:AZIENDA SANITARIA OSPEDALIERA "S. GIOVANNI BATTISTA DI TORINO"

Full Title: New therapeutic approaches for anaplastic thyroid cancer: assessment of the benefit-risk profile of the combination valproic acid-paclitaxel.

Medical condition: Patients with undifferentiated thyroid cancer

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	9.1		10002240	Anaplastic thyroid cancer	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: IT (Ongoing)

Trial results: (No results available)

EudraCT Number: 2022-001398-30	Sponsor Protocol Number: MEDOPP437	Start Date*: 2023-05-08
Sponsor Name:Medica Scientia Innovation Research, S.L.
Full Title: PHASE II STUDY FOR PIK3CA/PTEN-ALTERED ADVANCED METAPLASTIC BREAST CANCER TREATED WITH MEN1611 MONOTHERAPY OR IN COMBINATION WITH ERIBULIN -THE SABINA STUDY- English PHASE II STUDY WITH MEN1611 M...
Medical condition: Hormone Receptor (HR)-known/ Human Epidermial Growth Factor Receptor 2 (HER2)-negative, phosphatidylinositol-4,5-bisphosphate 3kinase catalytic subunit alpha (PIK3CA)/ Phosphatase and Tensin Homolo...
Disease:
Population Age: Adults, Elderly		Gender: Male, Female
Trial protocol: ES (Ongoing)
Trial results: (No results available)

EudraCT Number: 2017-004570-34

Sponsor Protocol Number: 01045-ATLEP

Start Date*: 2018-11-15

Sponsor Name:Medical Center - University of Freiburg

Full Title: Phase II, Open-label, Study in Patients with anaplastic (ATC) or poorly differentiated thyroid carcinomas (PDTC) to investigate the Clinical Efficacy and Safety of the Combination Therapy of Lenvat...

Medical condition: Anaplastic (ATC) or Poorly Differentiated Thyroid Carcinoma (PDTC)

Disease:	Version	SOC Term	Classification Code	Term	Level
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10076603	Poorly differentiated thyroid carcinoma	PT
	21.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10002240	Anaplastic thyroid cancer	PT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: DE (Completed)

Trial results: (No results available)

EudraCT Number: 2005-006191-35

Sponsor Protocol Number: D9612L00088

Start Date*: 2006-08-01

Sponsor Name:HSK, Dr. Horst Schmidt Kliniken GmbH

Full Title: Tumorfreies Überleben nach Ablation von Barrett-Schleimhaut Plus Esomeprazol versus tumorfreies Überleben unter Esomeprazol ohne Ablation von Barrett-Schleimhaut bei Patienten, die von einem „Barre...

Medical condition: Endoscopically treated Barrett-adenocarcinoma with complete remission

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	8.1		10004137	Barrett's oesophagus	PT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: DE (Prematurely Ended)

Trial results: (No results available)

EudraCT Number: 2007-002846-38

Sponsor Protocol Number: OXC4T4-302

Start Date*: 2007-12-06

Sponsor Name:OXiGENE, Inc.

Full Title: A multicenter, open-label, randomized, phase II/III study to evaluate the safety and efficacy of combretastatin a-4 phosphate in combination with paclitaxel and carboplatin in comparison with pacli...

Medical condition: Anaplastic Thyroid Carcinoma

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	9.1		10002240	Anaplastic thyroid cancer	PT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: GB (Prematurely Ended) IT (Completed) BG (Prematurely Ended)

Trial results: (No results available)

EudraCT Number: 2008-001032-12

Sponsor Protocol Number: PANTHERA

Start Date*: 2008-10-28

Sponsor Name:Universitätsklinikum Schleswig-Holstein

Full Title: Phase 2 trial of pemetrexed (Alimta™) combined with paclitaxel in patients with recurrent/advanced follicular, papillary or anaplastic thyroid cancer

Medical condition: recurrent/advanced follicular, papillary or anaplastic thyroid cancer

Disease:	Version	SOC Term	Classification Code	Term	Level
	14.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10016935	Follicular thyroid cancer	LLT
	14.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10002240	Anaplastic thyroid cancer	LLT
	14.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10033701	Papillary thyroid cancer	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: DE (Prohibited by CA)

Trial results: (No results available)

EudraCT Number: 2015-001929-17

Sponsor Protocol Number: E7080-M000-213

Start Date*: 2017-01-18

Sponsor Name:EISAI LIMITED

Full Title: This is an Open-Label, Single-Arm, Multicenter, Phase 2 Trial of Lenvatinib for the Treatment of Anaplastic Thyroid Cancer (ATC).

Medical condition: Anaplastic Thyroid Cancer (ATC)

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10002240	Anaplastic thyroid cancer	PT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: IT (Prematurely Ended)

Trial results: View results

EudraCT Number: 2017-004652-35

Sponsor Protocol Number: GIM22-ERICA

Start Date*: 2018-02-22

Sponsor Name:CONSORZIO ONCOTECH

Full Title: Second line ERIbulin followed by CApecitabine or the reverse sequence in HER2-negative Metastatic Breast Cancer (MBC) patients: a randomized phase II study – ERICA trial

Medical condition: HER2-negative Metastatic Breast Cancer

Disease:	Version	SOC Term	Classification Code	Term	Level
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10073100	Metaplastic breast carcinoma	PT
	20.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10055113	Breast cancer metastatic	PT

Population Age: Adults, Elderly

Gender: Female

Trial protocol: IT (Completed)

Trial results: (No results available)

EudraCT Number: 2018-001066-42

Sponsor Protocol Number: GETNE-T1812

Start Date*: 2020-02-20

Sponsor Name:Spanish Group of Neuroendocrine Tumors (GETNE)

Full Title: A phase II study of durvalumab (MEDI4736) plus tremelimumab for the treatment of patients with progressive, refractory advanced thyroid carcinoma - The DUTHY trial

Medical condition: Advanced, radioiodine-refractory differentiated thyroid carcinoma, including papillary, follicular, Hürtle Cell and poorly-differentiated thyroid carcinoma (DTC). Advanced medullary thyroid carcino...

Disease:	Version	SOC Term	Classification Code	Term	Level
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10076603	Poorly differentiated thyroid carcinoma	PT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10002240	Anaplastic thyroid cancer	PT
	20.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10016935	Follicular thyroid cancer	PT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10027105	Medullary thyroid cancer	PT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10033701	Papillary thyroid cancer	PT
	20.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10071027	Thyroid cancer stage I	PT
	20.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10071028	Thyroid cancer stage II	PT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: ES (Ongoing)

Trial results: (No results available)

EudraCT Number: 2016-002243-42

Sponsor Protocol Number: GCT1021-01

Start Date*: 2016-10-25

Sponsor Name:Genmab A/S

Full Title: First-in-human, open-label, dose-escalation trial with expansion cohorts to evaluate safety of Axl-specific antibody-drug conjugate (enapotamab vedotin, HuMax®-AXL-ADC) in patients with solid tumors.

Medical condition: Cancer of the ovary, cervix, endometrium, anaplastic thyroid, lung (non-small cell lung cancer [NSCLC]) or melanoma

Disease:	Version	SOC Term	Classification Code	Term	Level
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10014742	Endometrial neoplasms malignant	HLT
	21.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10008342	Cervix carcinoma	PT
	21.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10023774	Large cell lung cancer	PT
	21.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10002240	Anaplastic thyroid cancer	PT
	21.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10025650	Malignant melanoma	PT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10033128	Ovarian cancer	PT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10039491	Sarcoma	PT
	21.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10014733	Endometrial cancer	PT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: DK (Completed)

Trial results: View results

EudraCT Number: 2019-001388-55

Sponsor Protocol Number: CAPT

Start Date*: 2020-02-24

Sponsor Name:CONSORZIO ONCOTECH

Full Title: A Phase II Trial of atezolizumab plus carboplatin plus paclitaxel as first-line therapy in metastatic Triple-negative PD-L1 positive breast cancer patients

Medical condition: Metastatic Triple-negative PD-L1 positive breast cancer

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10073100	Metaplastic breast carcinoma	PT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: IT (Trial now transitioned)

Trial results: (No results available)

EudraCT Number: 2020-004163-12

Sponsor Protocol Number: 2020-012-GLOB1

Start Date*: 2021-11-04

Sponsor Name:Hutchison MediPharma Limited

Full Title: An Open-Label Phase Ib/II Study of Surufatinib in Combination with Tislelizumab in Subjects With Advanced Solid Tumors

Medical condition: Advanced Solid Tumors

Disease:	Version	SOC Term	Classification Code	Term	Level
	21.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10061451	Colorectal cancer	PT
	21.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10052399	Neuroendocrine tumour	PT
	21.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10059514	Small cell lung cancer metastatic	PT
	21.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10017758	Gastric cancer	PT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10075333	Soft tissue sarcoma	PT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: ES (Ongoing) FR (Completed)

Trial results: (No results available)

Subscribe to this Search
To subscribe to the RSS feed for this search click here

. This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.

Download Options:
Number of Trials to download:

Download Content:

Download Format:


Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.

Query did not match any studies.

For support, Contact us.

The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

European Medicines Agency © 1995-Tue May 27 20:33:14 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands

Austria
Belgium
Bulgaria
Croatia
Cyprus
Czechia
Denmark
Estonia
Finland
France
Germany
Greece
Hungary
Iceland
Ireland
Italy
Latvia
Liechtenstein
Lithuania
Luxembourg
Malta
Netherlands
Norway
Poland
Portugal
Romania
Slovakia
Slovenia
Spain
Sweden
United Kingdom
Outside EU/EEA